Atossa Therapeutics Announces a Virtual KOL Event on (Z)-Endoxifen Development in Breast Cancer Management
Atossa Therapeutics, a leading clinical-stage biopharmaceutical company, is set to host a significant virtual key opinion leader (KOL) event on May 19, 2026. This online event will primarily discuss the innovative advancements surrounding (Z)-endoxifen, the company’s investigational selective estrogen receptor modulator and degrader (SERM/D), which could play a crucial role in the treatment of estrogen receptor-positive breast cancer. The spotlight of the event will be on renowned surgical oncologist Dr. Laura Esserman, who is recognized for her pivotal contributions to breast cancer research and treatment methodologies.
Dr. Esserman serves as the Director of the University of California San Francisco Breast Care Center and has been instrumental in developing adaptive trial designs and precision oncology treatments. As the founder and principal investigator of the I-SPY Trials, Dr. Esserman’s involvement promises to bring to light the latest clinical and translational data supporting the capabilities of (Z)-endoxifen.
One of the key highlights of the event will be the recent data coming from the I-SPY2 Endocrine Optimization Pilot study. This study evaluates the effectiveness of (Z)-endoxifen as a standalone treatment for newly diagnosed ER-positive breast cancer patients, aiming to uncover crucial insights into its therapeutic potential. Participants can expect to receive information surrounding the drug’s action, particularly its ability to reduce biomarkers like Ki-67, as well as its impact on MRI functional tumor volume and circulating tumor DNA.
Moreover, attendees will learn about (Z)-endoxifen's efficacy against critical ESR1 mutations—Y537N, Y537S, and D538G—which are often associated with treatment resistance in breast cancer patients. Insights into the rationale behind positioning (Z)-endoxifen as not just a treatment option but a foundational therapy for multiple ER-positive breast cancer settings will also be discussed, urging a shift in current treatment paradigms.
The combination therapy strategies, particularly those involving CDK4/6 inhibitors in conjunction with (Z)-endoxifen, will form another focal point of the discussion. This aspect is crucial, as combination treatments are gaining traction in addressing the complex challenges posed by breast cancer.
A unique addition to this event will be the exploration of development opportunities concerning premenopausal breast cancer and the enhancement of endocrine therapy strategies. The discussion aims to elucidate how evolving data can guide future clinical applications and improve patient outcomes.
The virtual event is designed not only for medical professionals and researchers but also for investors and strategic partners interested in the groundbreaking work that Atossa is doing in the field of oncology. A Q&A session will allow attendees to submit their inquiries up to 24 hours before the event, ensuring that the discussion is as interactive and informative as possible.
Participants can register for the event via the provided Zoom link, and a recording will be made available on Atossa's website for those unable to attend the live discussion. This KOL event underscores Atossa's commitment to advancing breast cancer treatment and its dedication to leveraging clinical collaborations to improve therapeutic outcomes in oncology.
About (Z)-Endoxifen:
(Z)-endoxifen is recognized for its potent activity as a selective estrogen receptor modulator/degrader, promising to address breast cancer through various mechanisms. Current evaluations show a unique safety profile and pharmacological dynamics distinct from conventional treatments like tamoxifen. Though not yet approved for any specific indications, ongoing clinical evaluations aim to establish its efficacy further.
About Atossa Therapeutics:
Atossa Therapeutics is an innovative biopharmaceutical entity with a focus on developing cutting-edge therapies for unmet medical needs in oncology. Its primary candidate, (Z)-endoxifen, is at the center of a comprehensive and evolving clinical development program, underscoring the company’s pursuit of advancements in the treatment of breast cancer. As the company continues to expand its intellectual property portfolio and clinical partnerships, Atossa is positioned at the forefront of therapeutic innovation in cancer treatment.
Dr. Esserman serves as the Director of the University of California San Francisco Breast Care Center and has been instrumental in developing adaptive trial designs and precision oncology treatments. As the founder and principal investigator of the I-SPY Trials, Dr. Esserman’s involvement promises to bring to light the latest clinical and translational data supporting the capabilities of (Z)-endoxifen.
One of the key highlights of the event will be the recent data coming from the I-SPY2 Endocrine Optimization Pilot study. This study evaluates the effectiveness of (Z)-endoxifen as a standalone treatment for newly diagnosed ER-positive breast cancer patients, aiming to uncover crucial insights into its therapeutic potential. Participants can expect to receive information surrounding the drug’s action, particularly its ability to reduce biomarkers like Ki-67, as well as its impact on MRI functional tumor volume and circulating tumor DNA.
Moreover, attendees will learn about (Z)-endoxifen's efficacy against critical ESR1 mutations—Y537N, Y537S, and D538G—which are often associated with treatment resistance in breast cancer patients. Insights into the rationale behind positioning (Z)-endoxifen as not just a treatment option but a foundational therapy for multiple ER-positive breast cancer settings will also be discussed, urging a shift in current treatment paradigms.
The combination therapy strategies, particularly those involving CDK4/6 inhibitors in conjunction with (Z)-endoxifen, will form another focal point of the discussion. This aspect is crucial, as combination treatments are gaining traction in addressing the complex challenges posed by breast cancer.
A unique addition to this event will be the exploration of development opportunities concerning premenopausal breast cancer and the enhancement of endocrine therapy strategies. The discussion aims to elucidate how evolving data can guide future clinical applications and improve patient outcomes.
The virtual event is designed not only for medical professionals and researchers but also for investors and strategic partners interested in the groundbreaking work that Atossa is doing in the field of oncology. A Q&A session will allow attendees to submit their inquiries up to 24 hours before the event, ensuring that the discussion is as interactive and informative as possible.
Participants can register for the event via the provided Zoom link, and a recording will be made available on Atossa's website for those unable to attend the live discussion. This KOL event underscores Atossa's commitment to advancing breast cancer treatment and its dedication to leveraging clinical collaborations to improve therapeutic outcomes in oncology.
About (Z)-Endoxifen:
(Z)-endoxifen is recognized for its potent activity as a selective estrogen receptor modulator/degrader, promising to address breast cancer through various mechanisms. Current evaluations show a unique safety profile and pharmacological dynamics distinct from conventional treatments like tamoxifen. Though not yet approved for any specific indications, ongoing clinical evaluations aim to establish its efficacy further.
About Atossa Therapeutics:
Atossa Therapeutics is an innovative biopharmaceutical entity with a focus on developing cutting-edge therapies for unmet medical needs in oncology. Its primary candidate, (Z)-endoxifen, is at the center of a comprehensive and evolving clinical development program, underscoring the company’s pursuit of advancements in the treatment of breast cancer. As the company continues to expand its intellectual property portfolio and clinical partnerships, Atossa is positioned at the forefront of therapeutic innovation in cancer treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.